Tectonic Therapeutic, INC 8-K filings

Tectonic Therapeutic has successfully completed patient enrollment for its Phase 2 APEX trial of TX45 in PH-HFpEF patients, with topline results anticipated in early Q1 2027.

Tectonic Therapeutic has appointed veteran biotechnology investment banker Jessica Chutter to its Board of Directors, effective June 8, 2026.

Tectonic Therapeutic announced its fourth quarter and full year 2025 financial results, highlighting positive clinical trial data for TX45 and advancement of TX2100 into Phase 1a.

Tectonic Therapeutic announced the appointment of Dr. Franois Nader as its new independent Board Chair, effective April 1, 2026, alongside an update on its clinical-stage HHT therapy, TX2100.

Tectonic Therapeutic announced positive Phase 1b TX45 data, progress on its pipeline, and a cash runway into Q4 2028, alongside its third-quarter 2025 financial results.

Tectonic Therapeutic announced positive topline results from its Phase 1b Part B clinical trial for TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF).

Tectonic Therapeutic announced Q2 2025 financial results, positive Phase 1b TX45 data, and plans for new Phase 2 and Phase 1 trials, extending its cash runway into Q4 2028.

Tectonic Therapeutic, Inc. announced the successful outcomes of its 2025 Annual General Meeting, where stockholders elected two Class I directors, ratified Deloitte & Touche LLP as independent auditors, and approved executive compensation on an advisory basis, also indicating a preference for annual Say on Pay votes.

Tectonic Therapeutic reports positive complete results from its Phase 1b clinical trial of TX45, showing improved left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF).

Tectonic Therapeutic reports positive interim results from its TX45 Phase 1b trial, a successful private placement, and a cash runway extended into Q4 2028.

Tectonic Therapeutic reports positive interim results from its TX45 Phase 1b trial and secures $185 million in a private placement, extending its cash runway into Q4 2028.

Tectonic Therapeutic has successfully raised approximately $185 million through a private placement to fund its drug development programs and general operations.

Tectonic Therapeutic's TX45 demonstrated significant improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) in an interim Phase 1b trial.

Tectonic Therapeutic updated its corporate presentation, emphasizing the progress of its lead candidate TX45 in Phase 2 trials for pulmonary hypertension and its second candidate for a rare bleeding disorder.

Tectonic Therapeutic reported encouraging progress in its clinical trials, including faster than expected patient enrollment and the initiation of a Phase 2 trial, alongside its third quarter 2024 financial results.

Tectonic Therapeutic reports favorable Phase 1a safety, tolerability, and PK/PD results for its lead program TX45, a potential treatment for Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).

Tectonic Therapeutic reported its second quarter 2024 financial results, highlighted by the advancement of its lead drug candidate, TX45, into Phase 2 clinical trials and a successful reverse merger.

Tectonic Therapeutic has received FDA clearance for its Investigational New Drug application for TX45, a potential treatment for Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction.

Tectonic Therapeutic's Chief Operating Officer, Dr. Christian Cortis, has entered into a separation agreement, effective July 5, 2024, which includes severance pay, a prorated bonus, and a consulting arrangement.

Tectonic Therapeutic has updated its corporate presentation, detailing the design of its Phase 2 trial for TX45 and providing updates on its HHT program.

Tectonic Therapeutic has finalized its merger with AVROBIO, securing $130.7 million in a private placement and is now focused on advancing its pipeline of GPCR-targeted biologic therapies.

AVROBIO's merger with Tectonic Therapeutics is now expected to close around June 20, 2024, with a 1-for-12 reverse stock split effective the same day, and the combined company will trade under the ticker TECX starting June 21, 2024.

AVROBIO stockholders approved a 1-for-12 reverse stock split as part of the merger with Tectonic Therapeutics, with the combined company expected to begin trading under the ticker TECX on June 20, 2024.

AVROBIO, Inc. stockholders have approved the merger with Tectonic Therapeutics and several related proposals, including a reverse stock split and new equity incentive plans.

AVROBIO has voluntarily supplemented its merger disclosures following stockholder lawsuits alleging misrepresentations and omissions in the initial filings.

AVROBIO and Tectonic Therapeutics have agreed to merge, creating a combined entity focused on developing novel GPCR-targeted therapies, supported by a $130.7 million private financing.

AVROBIO and Tectonic Therapeutic have agreed to merge, forming a Nasdaq-listed clinical-stage biopharmaceutical company focused on advancing Tectonics novel GPCR-targeted therapeutic proteins, supported by a $130.7 million private financing.